Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Incyte, MorphoSys announce first patient dosed in Phase 3 frontMIND study » 16:04
05/11/21
05/11
16:04
05/11/21
16:04
INCY

Incyte

$80.70 /

-0.74 (-0.91%)

, MOR

MorphoSys

$20.42 /

+0.02 (+0.10%)

Incyte (INCY) and…

Incyte (INCY) and MorphoSys (MOR) announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma. Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation. "While more than half of DLBCL patients can be cured with an aggressive chemotherapy regimen, current outcomes for high-risk patients are poor," said Mike Akimov, M.D., Ph.D., Head of Global Drug Development, MorphoSys. "We believe we may be able to make a difference for those DLBCL patients by adding the combination of tafasitamab and lenalidomide to R-CHOP, a current standard of care."

ShowHide Related Items >><<
MOR MorphoSys
$20.42 /

+0.02 (+0.10%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
MOR MorphoSys
$20.42 /

+0.02 (+0.10%)

04/08/21 Deutsche Bank
MorphoSys price target lowered to EUR 116 from EUR 129 at Deutsche Bank
03/29/21 Morgan Stanley
MorphoSys price target lowered to EUR 91 from EUR 105 at Morgan Stanley
03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
MOR MorphoSys
$20.42 /

+0.02 (+0.10%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

INCY Incyte
$80.70 /

-0.74 (-0.91%)

Over a week ago
Hot Stocks
Incyte backs FY21 Jakafi revenue view $2.13B-$2.2B » 07:47
05/04/21
05/04
07:47
05/04/21
07:47
INCY

Incyte

/

+

Sees FY21 other…

Sees FY21 other hematology/oncology revenue $145M-$160M

ShowHide Related Items >><<
INCY Incyte
/

+

INCY Incyte
/

+

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
INCY Incyte
/

+

INCY Incyte
/

+

INCY Incyte
/

+

INCY Incyte
/

+

Earnings
Incyte reports Q1 EPS 67c, consensus 64c » 07:45
05/04/21
05/04
07:45
05/04/21
07:45
INCY

Incyte

/

+

Reports Q1 revenue…

Reports Q1 revenue $604.72M, consensus $659.24M. "In the first quarter, we continued to make significant progress in our strategy to drive growth and diversification. While Jakafi(R) (ruxolitinib) net sales were affected by typical seasonal effects and softer patient demand growth due to the ongoing pandemic, we remain confident in our full-year outlook. We are already seeing a return of new patient starts to pre-COVID levels and are excited for the potential launch in steroid-refractory chronic graft-versus-host disease (GVHD) later this year. The launches of Monjuvi(R) (tafasitamab) and Pemazyre(R) (pemigatinib) continue to progress with good uptake by both academic and community physicians," stated Herve Hoppenot, CEO, Incyte. "We expect an exciting year ahead for Incyte with the potential for multiple approvals, including ruxolitinib cream in atopic dermatitis, and several regulatory filings, notably parsaclisib in NHL and ruxolitinib cream in vitiligo. We are also initiating pivotal trials across key development programs for both tafasitamab and LIMBER this year."

ShowHide Related Items >><<
INCY Incyte
/

+

INCY Incyte
/

+

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
INCY Incyte
/

+

INCY Incyte
/

+

INCY Incyte
/

+

INCY Incyte
/

+

Hot Stocks
Incyte, Lilly announce new analyses of BREEZE-AD5 Phase 3 clinical trial data » 10:10
04/23/21
04/23
10:10
04/23/21
10:10
INCY

Incyte

$84.30 /

+0.12 (+0.14%)

, LLY

Eli Lilly

$187.92 /

+0.88 (+0.47%)

Through new analyses of…

Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly (LLY) and Incyte's (INCY) OLUMIANT 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis, the companies announced. "In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with OLUMIANT showed significant improvements in the severity and extent of disease compared to placebo. In the integrated safety analysis of eight AD studies of OLUMIANT, there were no increases in rates for treatment-emergent adverse events, serious adverse events or serious infections with long-term OLUMIANT therapy compared to the placebo-controlled period. These results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience, April 23-25," the companies said.

ShowHide Related Items >><<
LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

LLY Eli Lilly
$187.92 /

+0.88 (+0.47%)

INCY Incyte
$84.30 /

+0.12 (+0.14%)

Hot Stocks
Incyte announces new findings from pooled analyses of Phase 3 TRuE-AD program » 10:01
04/23/21
04/23
10:01
04/23/21
10:01
INCY

Incyte

$83.61 /

-0.57 (-0.68%)

Incyte announced findings…

Incyte announced findings from three pooled analyses of its randomized, double-blind, vehicle-controlled Phase 3 studies - TRuE-AD1 and TRuE-AD2 - evaluating ruxolitinib cream, an investigational JAK1/JAK2 inhibitor designed for topical application, as a treatment for patients with atopic dermatitis. These presentations will be available on demand as part of the American Academy of Dermatology Virtual Meeting Experience 2021, held virtually April 23-25, the company said. "Positive topline results from the individual TRuE-AD1 and TRuE-AD2 studies were previously reported. Efficacy and safety results from a pooled analysis of TRuE-AD1 and TRuE-AD2 were also announced and presented at the 29th European Academy of Dermatology and Venereology Congress in October 2020. The primary and secondary endpoints were met in both TRuE-AD1 and TRuE-AD2. New findings from the analyses being presented at AAD VMX add to the growing body of evidence on ruxolitinib cream as a potential treatment for AD," the company stated.

ShowHide Related Items >><<
INCY Incyte
$83.61 /

-0.57 (-0.68%)

INCY Incyte
$83.61 /

-0.57 (-0.68%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
INCY Incyte
$83.61 /

-0.57 (-0.68%)

INCY Incyte
$83.61 /

-0.57 (-0.68%)

INCY Incyte
$83.61 /

-0.57 (-0.68%)

INCY Incyte
$83.61 /

-0.57 (-0.68%)

Hot Stocks
Eli Lilly, Incyte announce results from BRAVE-AA1 trial » 06:58
04/20/21
04/20
06:58
04/20/21
06:58
LLY

Eli Lilly

$189.86 /

+0.58 (+0.31%)

, INCY

Incyte

$82.59 /

-0.05 (-0.06%)

Eli Lilly (LLY) and…

Eli Lilly (LLY) and Incyte (INCY) announced results from a second Phase 3 trial, BRAVE-AA1, evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata, or AA. The data are consistent with findings from the first Phase 3 clinical trial, BRAVE-AA2, top-lined earlier this year. In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress, and currently has no therapies approved by the FDA. In both studies, over the nine-month treatment period, patients with severe AA treated with baricitinib 2-mg and 4-mg doses experienced significantly greater scalp hair regrowth compared to patients treated with placebo based on physician's assessment. Results of BRAVE-AA1 showed that atWeek 36,the proportion of patients reaching 80 percent or more scalp hair coveragewasachievedby 35 of patients treated with baricitinib 4-mg/day, 22% of patients treated withbaricitinib2-mg/day and 5% percent of patients in the placebo group, meeting the primary endpoint. BRAVE-AA2 showed that at Week 36 the proportion of patients reaching 80 percent or more scalp hair coverage was achieved by 33 percent (pless than or equal to0.001) of patients treated withbaricitinib4-mg/day, 17 percent (pless than or equal to0.001) of patients treated with baricitinib 2-mg/day and three percent of patients in the placebo group, meeting the primary endpoint. Across both studies, the proportion of patients self-reporting at least 80 percent scalp hair coverage was significantly greater in the 2-mg and 4-mg groups compared to placebo by Week 36. The most common treatment-emergent adverse events, or TEAEs, in BRAVE-AA1 and BRAVE-AA2 included upper respiratory tract infections, headache and acne. No deaths or venous thromboembolic events, or VTEs, were reported in the trials. The safety profile of baricitinib in the two studies was consistent with its known safety profile in patients with rheumatoid arthritis, or RA, and atopic dermatitis, or AD. Lilly will present detailed data from these studies at scientific meetings later this year and submit the results to peer-reviewed journals. Based on these results, Lilly plans to submit a supplemental New Drug Application to the FDA for baricitinib in AA in the second half of 2021, followed by submissions to other regulatory agencies around the world.

ShowHide Related Items >><<
LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

INCY Incyte
$82.59 /

-0.05 (-0.06%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
INCY Incyte
$82.59 /

-0.05 (-0.06%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

INCY Incyte
$82.59 /

-0.05 (-0.06%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

INCY Incyte
$82.59 /

-0.05 (-0.06%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

INCY Incyte
$82.59 /

-0.05 (-0.06%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

INCY Incyte
$82.59 /

-0.05 (-0.06%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/15/21
04/15
04:55
04/15/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$35.13 /

-0.92 (-2.55%)

, JNCE

Jounce Therapeutics

$9.74 /

+0.485 (+5.24%)

, ATNM

Actinium Pharmaceuticals

$7.80 /

+0.23 (+3.04%)

, BDTX

Black Diamond Therapeutics

$24.70 /

-0.7199 (-2.83%)

, CRSP

Crispr Therapeutics

$123.29 /

+2.34 (+1.93%)

, HARP

Harpoon Therapeutics

$20.61 /

+0.73 (+3.67%)

, ITOS

iTeos Therapeutics

$24.03 /

-1.24 (-4.91%)

, REPL

Replimune Group

$30.50 /

+0.32 (+1.06%)

, RVMD

Revolution Medicines

$39.79 /

+2.18 (+5.80%)

, ZNTL

Zentalis

$47.04 /

+1.43 (+3.14%)

, IMCR

Immunocore

$39.50 /

+6.8 (+20.80%)

, PMVP

PMV Pharmaceuticals

$32.90 /

+0.06 (+0.18%)

, ARVN

Arvinas

$62.89 /

+1.62 (+2.64%)

, IOVA

Iovance Biotherapeutics

$30.00 /

-0.17 (-0.56%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.70 /

-0.015 (-0.55%)

, BPTH

Bio-Path

$6.21 /

-0.41 (-6.19%)

, INCY

Incyte

$82.13 /

+1.5 (+1.86%)

, IMAB

I-MAB

$55.17 /

+5.42 (+10.89%)

, MRSN

Mersana Therapeutics

$17.06 /

+0.89 (+5.50%)

, RUBY

Rubius Therapeutics

$23.77 /

+1.27 (+5.64%)

, PPBT

Purple Biotech

$4.04 /

+ (+0.00%)

, SONN

Sonnet BioTherapeutics

$2.11 /

-0.02 (-0.94%)

, STTK

Shattuck Labs

$32.98 /

+0.56 (+1.73%)

, SURF

Surface Oncology

$7.35 /

+0.095 (+1.31%)

, BGNE

BeiGene

$300.84 /

+0.84 (+0.28%)

, CMPI

Checkmate Pharmaceuticals

$7.44 /

+0.3 (+4.20%)

, BNGO

Bionano Genomics

$6.42 /

-0.47 (-6.82%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on April 9-15. Webcast Link

ShowHide Related Items >><<
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

SONN Sonnet BioTherapeutics
$2.11 /

-0.02 (-0.94%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PPBT Purple Biotech
$4.04 /

+ (+0.00%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

IMAB I-MAB
$55.17 /

+5.42 (+10.89%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

ADXS Advaxis
/

+

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

04/12/21 Piper Sandler
iTeos Therapeutics' EOS-448 'competitive' in TIGIT class, says Piper Sandler
04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

04/12/21 SVB Leerink
Zentalis price target raised to $60 from $44 at SVB Leerink
03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

04/13/21 Cowen
Cowen starts Instil Bio at Outperform on 'second-mover advantage'
03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
ADXS Advaxis
/

+

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$82.13 /

+1.5 (+1.86%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$55.17 /

+5.42 (+10.89%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.04 /

+ (+0.00%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.11 /

-0.02 (-0.94%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

ADXS Advaxis
/

+

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 04
    Feb
  • 05
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
INCY Incyte
$82.13 /

+1.5 (+1.86%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PPBT Purple Biotech
$4.04 /

+ (+0.00%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/14/21
04/14
04:55
04/14/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$35.97 /

-3.06 (-7.84%)

, JNCE

Jounce Therapeutics

$9.25 /

+0.13 (+1.43%)

, ATNM

Actinium Pharmaceuticals

$7.57 /

-0.23 (-2.95%)

, BDTX

Black Diamond Therapeutics

$25.51 /

+0.94 (+3.83%)

, CRSP

Crispr Therapeutics

$120.95 /

+6.56 (+5.73%)

, HARP

Harpoon Therapeutics

$19.88 /

-0.54 (-2.64%)

, ITOS

iTeos Therapeutics

$24.95 /

+0.89 (+3.70%)

, REPL

Replimune Group

$30.27 /

+0.985 (+3.36%)

, RVMD

Revolution Medicines

$37.61 /

-1.69 (-4.30%)

, ZNTL

Zentalis

$45.62 /

+5.43 (+13.51%)

, IMCR

Immunocore

$32.75 /

+0.53 (+1.64%)

, PMVP

PMV Pharmaceuticals

$32.82 /

+1.88 (+6.08%)

, ARVN

Arvinas

$61.27 /

+0.79 (+1.31%)

, IOVA

Iovance Biotherapeutics

$30.17 /

+0.76 (+2.58%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.71 /

+0.045 (+1.69%)

, BPTH

Bio-Path

$6.60 /

+0.29 (+4.60%)

, INCY

Incyte

$80.61 /

+0.78 (+0.98%)

, IMAB

I-MAB

$49.75 /

+2.05 (+4.30%)

, MRSN

Mersana Therapeutics

$16.17 /

+0.315 (+1.99%)

, RUBY

Rubius Therapeutics

$22.60 /

+0.35 (+1.57%)

, PPBT

Purple Biotech

$4.04 /

-0.02 (-0.49%)

, SONN

Sonnet BioTherapeutics

$2.13 /

+ (+0.00%)

, STTK

Shattuck Labs

$32.42 /

+1.795 (+5.86%)

, SURF

Surface Oncology

$7.25 /

+0.025 (+0.35%)

, BGNE

BeiGene

$300.00 /

+5.01 (+1.70%)

, CMPI

Checkmate Pharmaceuticals

$7.15 /

-1.39 (-16.28%)

, BNGO

Bionano Genomics

$6.89 /

+0.145 (+2.15%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on April 9-15. Webcast Link

ShowHide Related Items >><<
ZNTL Zentalis
$45.62 /

+5.43 (+13.51%)

SURF Surface Oncology
$7.25 /

+0.025 (+0.35%)

STTK Shattuck Labs
$32.42 /

+1.795 (+5.86%)

SONN Sonnet BioTherapeutics
$2.13 /

+ (+0.00%)

RVMD Revolution Medicines
$37.61 /

-1.69 (-4.30%)

RUBY Rubius Therapeutics
$22.60 /

+0.35 (+1.57%)

REPL Replimune Group
$30.27 /

+0.985 (+3.36%)

PPBT Purple Biotech
$4.04 /

-0.02 (-0.49%)

PMVP PMV Pharmaceuticals
$32.82 /

+1.88 (+6.08%)

MRSN Mersana Therapeutics
$16.17 /

+0.315 (+1.99%)

JNCE Jounce Therapeutics
$9.25 /

+0.13 (+1.43%)

ITOS iTeos Therapeutics
$24.95 /

+0.89 (+3.70%)

IOVA Iovance Biotherapeutics
$30.17 /

+0.76 (+2.58%)

INCY Incyte
$80.61 /

+0.78 (+0.98%)

IMCR Immunocore
$32.75 /

+0.53 (+1.64%)

IMAB I-MAB
$49.75 /

+2.05 (+4.30%)

HARP Harpoon Therapeutics
$19.88 /

-0.54 (-2.64%)

GLSI Greenwich LifeSciences
$35.97 /

-3.06 (-7.84%)

CRSP Crispr Therapeutics
$120.95 /

+6.56 (+5.73%)

CMPI Checkmate Pharmaceuticals
$7.15 /

-1.39 (-16.28%)

BPTH Bio-Path
$6.60 /

+0.29 (+4.60%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

BGNE BeiGene
$300.00 /

+5.01 (+1.70%)

BDTX Black Diamond Therapeutics
$25.51 /

+0.94 (+3.83%)

ATNM Actinium Pharmaceuticals
$7.57 /

-0.23 (-2.95%)

ARVN Arvinas
$61.27 /

+0.79 (+1.31%)

AGEN Agenus
$2.71 /

+0.045 (+1.69%)

ADXS Advaxis
/

+

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$35.97 /

-3.06 (-7.84%)

JNCE Jounce Therapeutics
$9.25 /

+0.13 (+1.43%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$7.57 /

-0.23 (-2.95%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$25.51 /

+0.94 (+3.83%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$120.95 /

+6.56 (+5.73%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$19.88 /

-0.54 (-2.64%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$24.95 /

+0.89 (+3.70%)

04/12/21 Piper Sandler
iTeos Therapeutics' EOS-448 'competitive' in TIGIT class, says Piper Sandler
04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
REPL Replimune Group
$30.27 /

+0.985 (+3.36%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$37.61 /

-1.69 (-4.30%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$45.62 /

+5.43 (+13.51%)

04/12/21 SVB Leerink
Zentalis price target raised to $60 from $44 at SVB Leerink
03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
IMCR Immunocore
$32.75 /

+0.53 (+1.64%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$32.82 /

+1.88 (+6.08%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$61.27 /

+0.79 (+1.31%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$30.17 /

+0.76 (+2.58%)

04/13/21 Cowen
Cowen starts Instil Bio at Outperform on 'second-mover advantage'
03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
ADXS Advaxis
/

+

AGEN Agenus
$2.71 /

+0.045 (+1.69%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.60 /

+0.29 (+4.60%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$80.61 /

+0.78 (+0.98%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$49.75 /

+2.05 (+4.30%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$16.17 /

+0.315 (+1.99%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$22.60 /

+0.35 (+1.57%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.04 /

-0.02 (-0.49%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.13 /

+ (+0.00%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$32.42 /

+1.795 (+5.86%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
SURF Surface Oncology
$7.25 /

+0.025 (+0.35%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$300.00 /

+5.01 (+1.70%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$7.15 /

-1.39 (-16.28%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
ZNTL Zentalis
$45.62 /

+5.43 (+13.51%)

SURF Surface Oncology
$7.25 /

+0.025 (+0.35%)

STTK Shattuck Labs
$32.42 /

+1.795 (+5.86%)

RVMD Revolution Medicines
$37.61 /

-1.69 (-4.30%)

RUBY Rubius Therapeutics
$22.60 /

+0.35 (+1.57%)

REPL Replimune Group
$30.27 /

+0.985 (+3.36%)

PMVP PMV Pharmaceuticals
$32.82 /

+1.88 (+6.08%)

MRSN Mersana Therapeutics
$16.17 /

+0.315 (+1.99%)

JNCE Jounce Therapeutics
$9.25 /

+0.13 (+1.43%)

ITOS iTeos Therapeutics
$24.95 /

+0.89 (+3.70%)

IOVA Iovance Biotherapeutics
$30.17 /

+0.76 (+2.58%)

INCY Incyte
$80.61 /

+0.78 (+0.98%)

IMCR Immunocore
$32.75 /

+0.53 (+1.64%)

HARP Harpoon Therapeutics
$19.88 /

-0.54 (-2.64%)

CRSP Crispr Therapeutics
$120.95 /

+6.56 (+5.73%)

CMPI Checkmate Pharmaceuticals
$7.15 /

-1.39 (-16.28%)

BPTH Bio-Path
$6.60 /

+0.29 (+4.60%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

BGNE BeiGene
$300.00 /

+5.01 (+1.70%)

BDTX Black Diamond Therapeutics
$25.51 /

+0.94 (+3.83%)

ARVN Arvinas
$61.27 /

+0.79 (+1.31%)

AGEN Agenus
$2.71 /

+0.045 (+1.69%)

ADXS Advaxis
/

+

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 04
    Feb
  • 05
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
INCY Incyte
$80.61 /

+0.78 (+0.98%)

GLSI Greenwich LifeSciences
$35.97 /

-3.06 (-7.84%)

SURF Surface Oncology
$7.25 /

+0.025 (+0.35%)

RVMD Revolution Medicines
$37.61 /

-1.69 (-4.30%)

RUBY Rubius Therapeutics
$22.60 /

+0.35 (+1.57%)

REPL Replimune Group
$30.27 /

+0.985 (+3.36%)

MRSN Mersana Therapeutics
$16.17 /

+0.315 (+1.99%)

JNCE Jounce Therapeutics
$9.25 /

+0.13 (+1.43%)

INCY Incyte
$80.61 /

+0.78 (+0.98%)

IMCR Immunocore
$32.75 /

+0.53 (+1.64%)

HARP Harpoon Therapeutics
$19.88 /

-0.54 (-2.64%)

GLSI Greenwich LifeSciences
$35.97 /

-3.06 (-7.84%)

CRSP Crispr Therapeutics
$120.95 /

+6.56 (+5.73%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

ATNM Actinium Pharmaceuticals
$7.57 /

-0.23 (-2.95%)

ARVN Arvinas
$61.27 /

+0.79 (+1.31%)

ZNTL Zentalis
$45.62 /

+5.43 (+13.51%)

RVMD Revolution Medicines
$37.61 /

-1.69 (-4.30%)

REPL Replimune Group
$30.27 /

+0.985 (+3.36%)

PPBT Purple Biotech
$4.04 /

-0.02 (-0.49%)

PMVP PMV Pharmaceuticals
$32.82 /

+1.88 (+6.08%)

INCY Incyte
$80.61 /

+0.78 (+0.98%)

CRSP Crispr Therapeutics
$120.95 /

+6.56 (+5.73%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

BDTX Black Diamond Therapeutics
$25.51 /

+0.94 (+3.83%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/13/21
04/13
04:55
04/13/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$39.03 /

-14.47 (-27.05%)

, JNCE

Jounce Therapeutics

$9.12 /

-0.64 (-6.56%)

, ATNM

Actinium Pharmaceuticals

$7.80 /

-0.3 (-3.70%)

, BDTX

Black Diamond Therapeutics

$24.76 /

+0.15 (+0.61%)

, CRSP

Crispr Therapeutics

$114.42 /

-1.27 (-1.10%)

, HARP

Harpoon Therapeutics

$20.31 /

-2.35 (-10.37%)

, ITOS

iTeos Therapeutics

$24.07 /

-2.84 (-10.56%)

, REPL

Replimune Group

$29.39 /

-0.65 (-2.16%)

, RVMD

Revolution Medicines

$39.30 /

-3.39 (-7.94%)

, ZNTL

Zentalis

$40.50 /

+3 (+8.00%)

, IMCR

Immunocore

$32.22 /

-3.28 (-9.24%)

, PMVP

PMV Pharmaceuticals

$31.09 /

-2.245 (-6.73%)

, ARVN

Arvinas

$60.49 /

-3.06 (-4.82%)

, IOVA

Iovance Biotherapeutics

$29.41 /

-0.74 (-2.45%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.67 /

-0.115 (-4.14%)

, BPTH

Bio-Path

$6.31 /

-0.45 (-6.66%)

, INCY

Incyte

$79.83 /

-0.12 (-0.15%)

, IMAB

I-MAB

$47.74 /

-3.76 (-7.30%)

, MRSN

Mersana Therapeutics

$15.85 /

+0.04 (+0.25%)

, RUBY

Rubius Therapeutics

$22.31 /

-1.61 (-6.73%)

, PPBT

Purple Biotech

$4.05 /

-0.27 (-6.25%)

, SONN

Sonnet BioTherapeutics

$2.13 /

-0.11 (-4.91%)

, STTK

Shattuck Labs

$30.59 /

+1.98 (+6.92%)

, SURF

Surface Oncology

$7.22 /

-0.71 (-8.95%)

, BGNE

BeiGene

$294.41 /

-14.14 (-4.58%)

, CMPI

Checkmate Pharmaceuticals

$8.37 /

-2.15 (-20.44%)

, BNGO

Bionano Genomics

$6.75 /

-0.535 (-7.34%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on April 9-15. Webcast Link

ShowHide Related Items >><<
ZNTL Zentalis
$40.50 /

+3 (+8.00%)

SURF Surface Oncology
$7.22 /

-0.71 (-8.95%)

STTK Shattuck Labs
$30.59 /

+1.98 (+6.92%)

SONN Sonnet BioTherapeutics
$2.13 /

-0.11 (-4.91%)

RVMD Revolution Medicines
$39.30 /

-3.39 (-7.94%)

RUBY Rubius Therapeutics
$22.31 /

-1.61 (-6.73%)

REPL Replimune Group
$29.39 /

-0.65 (-2.16%)

PPBT Purple Biotech
$4.05 /

-0.27 (-6.25%)

PMVP PMV Pharmaceuticals
$31.09 /

-2.245 (-6.73%)

MRSN Mersana Therapeutics
$15.85 /

+0.04 (+0.25%)

JNCE Jounce Therapeutics
$9.12 /

-0.64 (-6.56%)

ITOS iTeos Therapeutics
$24.07 /

-2.84 (-10.56%)

IOVA Iovance Biotherapeutics
$29.41 /

-0.74 (-2.45%)

INCY Incyte
$79.83 /

-0.12 (-0.15%)

IMCR Immunocore
$32.22 /

-3.28 (-9.24%)

IMAB I-MAB
$47.74 /

-3.76 (-7.30%)

HARP Harpoon Therapeutics
$20.31 /

-2.35 (-10.37%)

GLSI Greenwich LifeSciences
$39.03 /

-14.47 (-27.05%)

CRSP Crispr Therapeutics
$114.42 /

-1.27 (-1.10%)

CMPI Checkmate Pharmaceuticals
$8.37 /

-2.15 (-20.44%)

BPTH Bio-Path
$6.31 /

-0.45 (-6.66%)

BNGO Bionano Genomics
$6.75 /

-0.535 (-7.34%)

BGNE BeiGene
$294.41 /

-14.14 (-4.58%)

BDTX Black Diamond Therapeutics
$24.76 /

+0.15 (+0.61%)

ATNM Actinium Pharmaceuticals
$7.80 /

-0.3 (-3.70%)

ARVN Arvinas
$60.49 /

-3.06 (-4.82%)

AGEN Agenus
$2.67 /

-0.115 (-4.14%)

ADXS Advaxis
/

+

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$39.03 /

-14.47 (-27.05%)

JNCE Jounce Therapeutics
$9.12 /

-0.64 (-6.56%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$7.80 /

-0.3 (-3.70%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$24.76 /

+0.15 (+0.61%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$114.42 /

-1.27 (-1.10%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$20.31 /

-2.35 (-10.37%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$24.07 /

-2.84 (-10.56%)

04/12/21 Piper Sandler
iTeos Therapeutics' EOS-448 'competitive' in TIGIT class, says Piper Sandler
04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
REPL Replimune Group
$29.39 /

-0.65 (-2.16%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$39.30 /

-3.39 (-7.94%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$40.50 /

+3 (+8.00%)

04/12/21 SVB Leerink
Zentalis price target raised to $60 from $44 at SVB Leerink
03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
IMCR Immunocore
$32.22 /

-3.28 (-9.24%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$31.09 /

-2.245 (-6.73%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$60.49 /

-3.06 (-4.82%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$29.41 /

-0.74 (-2.45%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
ADXS Advaxis
/

+

AGEN Agenus
$2.67 /

-0.115 (-4.14%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.31 /

-0.45 (-6.66%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$79.83 /

-0.12 (-0.15%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$47.74 /

-3.76 (-7.30%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$15.85 /

+0.04 (+0.25%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$22.31 /

-1.61 (-6.73%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.05 /

-0.27 (-6.25%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.13 /

-0.11 (-4.91%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$30.59 /

+1.98 (+6.92%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
SURF Surface Oncology
$7.22 /

-0.71 (-8.95%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$294.41 /

-14.14 (-4.58%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$8.37 /

-2.15 (-20.44%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$6.75 /

-0.535 (-7.34%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
ZNTL Zentalis
$40.50 /

+3 (+8.00%)

SURF Surface Oncology
$7.22 /

-0.71 (-8.95%)

STTK Shattuck Labs
$30.59 /

+1.98 (+6.92%)

RVMD Revolution Medicines
$39.30 /

-3.39 (-7.94%)

RUBY Rubius Therapeutics
$22.31 /

-1.61 (-6.73%)

REPL Replimune Group
$29.39 /

-0.65 (-2.16%)

PMVP PMV Pharmaceuticals
$31.09 /

-2.245 (-6.73%)

MRSN Mersana Therapeutics
$15.85 /

+0.04 (+0.25%)

JNCE Jounce Therapeutics
$9.12 /

-0.64 (-6.56%)

ITOS iTeos Therapeutics
$24.07 /

-2.84 (-10.56%)

IOVA Iovance Biotherapeutics
$29.41 /

-0.74 (-2.45%)

INCY Incyte
$79.83 /

-0.12 (-0.15%)

IMCR Immunocore
$32.22 /

-3.28 (-9.24%)

HARP Harpoon Therapeutics
$20.31 /

-2.35 (-10.37%)

CRSP Crispr Therapeutics
$114.42 /

-1.27 (-1.10%)

CMPI Checkmate Pharmaceuticals
$8.37 /

-2.15 (-20.44%)

BPTH Bio-Path
$6.31 /

-0.45 (-6.66%)

BNGO Bionano Genomics
$6.75 /

-0.535 (-7.34%)

BGNE BeiGene
$294.41 /

-14.14 (-4.58%)

BDTX Black Diamond Therapeutics
$24.76 /

+0.15 (+0.61%)

ARVN Arvinas
$60.49 /

-3.06 (-4.82%)

AGEN Agenus
$2.67 /

-0.115 (-4.14%)

ADXS Advaxis
/

+

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 04
    Feb
  • 05
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
INCY Incyte
$79.83 /

-0.12 (-0.15%)

GLSI Greenwich LifeSciences
$39.03 /

-14.47 (-27.05%)

SURF Surface Oncology
$7.22 /

-0.71 (-8.95%)

RVMD Revolution Medicines
$39.30 /

-3.39 (-7.94%)

RUBY Rubius Therapeutics
$22.31 /

-1.61 (-6.73%)

REPL Replimune Group
$29.39 /

-0.65 (-2.16%)

MRSN Mersana Therapeutics
$15.85 /

+0.04 (+0.25%)

JNCE Jounce Therapeutics
$9.12 /

-0.64 (-6.56%)

INCY Incyte
$79.83 /

-0.12 (-0.15%)

IMCR Immunocore
$32.22 /

-3.28 (-9.24%)

HARP Harpoon Therapeutics
$20.31 /

-2.35 (-10.37%)

GLSI Greenwich LifeSciences
$39.03 /

-14.47 (-27.05%)

CRSP Crispr Therapeutics
$114.42 /

-1.27 (-1.10%)

BNGO Bionano Genomics
$6.75 /

-0.535 (-7.34%)

ATNM Actinium Pharmaceuticals
$7.80 /

-0.3 (-3.70%)

ARVN Arvinas
$60.49 /

-3.06 (-4.82%)

ZNTL Zentalis
$40.50 /

+3 (+8.00%)

RVMD Revolution Medicines
$39.30 /

-3.39 (-7.94%)

REPL Replimune Group
$29.39 /

-0.65 (-2.16%)

PPBT Purple Biotech
$4.05 /

-0.27 (-6.25%)

PMVP PMV Pharmaceuticals
$31.09 /

-2.245 (-6.73%)

INCY Incyte
$79.83 /

-0.12 (-0.15%)

CRSP Crispr Therapeutics
$114.42 /

-1.27 (-1.10%)

BNGO Bionano Genomics
$6.75 /

-0.535 (-7.34%)

BDTX Black Diamond Therapeutics
$24.76 /

+0.15 (+0.61%)

Over a month ago
Conference/Events
Incyte to hold a conference call » 08:25
04/12/21
04/12
08:25
04/12/21
08:25
INCY

Incyte

$79.97 /

-0.91 (-1.13%)

Management discusses…

Management discusses highlights of the Adenosine Program as presented at the AACR Annual Meeting on a conference call to be held on April 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
INCY Incyte
$79.97 /

-0.91 (-1.13%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
INCY Incyte
$79.97 /

-0.91 (-1.13%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.